SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Alivus Life Sciences - Quaterly Results

23 Jan 2026 Evaluate
With no major difference for the quarter endedDecember 2025 , the total revenue stood at Rs. 6728.89  millions.The Company has registered profit of Rs. 1502.61  millions for the quarter ended December 2025, a growth of 9.71%  over Rs. 1369.60 millions millions achieved in the corresponding quarter of last year.Operating profit surged to 2452.01 millions from the corresponding previous quarter of 2007.64 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202512 202412 % Var 202512 202412 % Var 202503 202403 % Var
Sales 6728.89 6418.44 4.84 18627.15 17373.39 7.22 23868.84 22832.14 4.54
Other Income 139.28 104.56 33.21 376.33 244.82 53.72 345.70 120.42 187.08
PBIDT 2452.01 2007.64 22.13 6203.87 5086.34 21.97 7171.54 6862.88 4.50
Interest 14.94 4.58 226.20 40.63 11.54 252.08 24.14 15.46 56.14
PBDT 2180.50 2003.06 8.86 5906.67 5074.80 16.39 7147.40 6847.42 4.38
Depreciation 196.58 151.59 29.68 551.57 446.39 23.56 606.09 534.52 13.39
PBT 1983.92 1851.47 7.15 5355.10 4628.41 15.70 6541.31 6312.90 3.62
TAX 481.31 481.87 -0.12 1336.88 1190.82 12.27 1685.04 1604.02 5.05
Deferred Tax -57.85 13.81 -518.90 8.85 45.19 -80.42 60.64 81.88 -25.94
PAT 1502.61 1369.60 9.71 4018.22 3437.59 16.89 4856.27 4708.88 3.13
Equity 245.36 245.07 0.12 245.36 245.07 0.12 245.07 245.05 0.01
PBIDTM(%) 36.44 31.28 16.50 33.31 29.28 13.76 30.05 30.06 -0.04

Alivus Life Sciences Share Price

1042.50 -0.70 (-0.07%)
13-Apr-2026 15:40 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1652.00
Dr. Reddys Lab 1235.00
Cipla 1211.30
Zydus Lifesciences 920.00
Lupin 2316.10
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×